Success Stories: Japanese Postdoctoral Fellow Earns EB1A Approval for Groundbreaking Work in Cardiac and Neurodegenerative Disease Treatment
Client’s Testimonial:
“Thank you for supporting me very well.”
On October 2nd, 2025, we received another EB1A (Alien of Extraordinary Ability) approval for a Postdoctoral Fellow in the field of Integrative Healthcare Research (Approval Notice).
General Field: Integrative Healthcare Research
Position at the Time of Case Filing: Postdoctoral Fellow
Country of Origin: Japan
State of Residence at the Time of Filing: Ohio
Approval Notice Date: October 2nd, 2025
Processing Time: 17 days (Premium Processing Requested)
Case Summary:
We are pleased to share the EB1A approval of a postdoctoral fellow from Japan whose pioneering work bridges neuroscience and cardiology. At the time of filing, the client was conducting advanced translational research on neurodegenerative and cardiovascular diseases, with a focus on Parkinson’s disease, atrial fibrillation, and cardiac device safety. Her impactful publication record, citation influence, and extensive peer review service established her as a distinguished candidate for EB1A approval.
Extraordinary Research Contributions
The client’s research integrates neuroscience and cardiology to advance medical care and patient safety. Her studies have revealed neuroprotective mechanisms in Parkinson’s disease, guided best practices for anticoagulation therapy after atrial fibrillation ablation, and provided some of the earliest large-scale assessments of leadless pacemaker safety. Collectively, her findings have advanced both scientific understanding and clinical practice, contributing to improved outcomes for patients worldwide.
Academic Record and Recognition
The client holds a Ph.D. in medical sciences and an M.D., combining clinical precision with research innovation. She has authored 28 peer-reviewed journal articles, 9 abstracts, and 1 book chapter, with work published in leading journals such as the European Heart Journal, Nature Communications, JACC: Clinical Electrophysiology, and Circulation: Arrhythmia and Electrophysiology. Her research has been cited 262 times by independent scholars across 37 countries, with several papers ranked among the top 1% of most-cited papers in clinical medicine.
She has also completed 27 peer reviews for major journals, including Heart Rhythm, BMC Public Health, and Scientific Reports, reflecting her recognition as a trusted expert in her field. Her research has informed international guidelines from the European Cardiac Arrhythmias Society and has been adopted by research teams at major universities and medical device companies, underscoring its global impact.
Expert Endorsements
Independent experts emphasized both the originality and the applied value of her work.
One recommender stated:
“Overall, [client]’s research provides insights that advance clinical decisions, hospital policies, and patient outcomes nationwide.”
This testimony reflects her influence as a researcher whose findings directly inform clinical innovation and healthcare policy.
EB1A Approval and Outlook
The I-140 EB1A petition was filed on September 15, 2025, and approved on October 2, 2025, under premium processing. USCIS recognized her publication record, citation impact, and the significant clinical relevance of her research as clear evidence of extraordinary ability.
With NAILG’s support, the client achieved EB1A approval and continues her research in the United States, where she is developing AI-driven models to predict disease outcomes and support new therapies. Her ongoing work strengthens U.S. leadership in precision medicine, bridging neuroscience, cardiology, and artificial intelligence to improve global health outcomes.